File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Molecular therapeutics of HBV.

TitleMolecular therapeutics of HBV.
Authors
Issue Date2003
PublisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cgt/index.htm
Citation
Current Gene Therapy, 2003, v. 3 n. 4, p. 341-355 How to Cite?
AbstractThe hepatitis B virus (HBV) infection is a public health problem worldwide, particularly in East Asia. The current therapy of HBV infection is mostly based on chemical agents and cytokines that have been shown to provide limited efficacy and are also toxic to the human body. Gene therapy is a new therapeutic strategy against HBV infection, involving the transmission of gene drugs into liver cells by specific delivery systems and methods. Although this new anti-HBV infection technique is under active investigation, various promising anti-HBV viral gene drugs have been developed for gene therapy, including antisense RNA and DNA, hammerhead ribozymes, dominant negative HBV core mutants, single chain antibody, co-nuclease fusion protein, and antigen. In order to optimize their antiviral effects and/or enhance anti-HBV immunity, various novel gene delivery systems have also been developed to (specifically) deliver such DNA constructs into liver cells; some of them are viral vectors, such as adenoviral vectors, retroviral vectors and poxviral vectors, and even hepatitis B viral for its hepatocellular specificity. Others are non-viral vectors, in which naked DNA and liposomes are frequently used for DNA vaccine or nucleotide analogs for inhibiting HBV DNA polymerase. This review addresses various aspects of gene therapy for HBV infection, including gene drugs, delivery methods, animal model, and liver transplantation with combination therapy. It also discusses the problems that remain to be solved.
Persistent Identifierhttp://hdl.handle.net/10722/84581
ISSN
2015 Impact Factor: 2.738
2015 SCImago Journal Rankings: 1.095

 

DC FieldValueLanguage
dc.contributor.authorXu, Ren_HK
dc.contributor.authorCai, Ken_HK
dc.contributor.authorZheng, Den_HK
dc.contributor.authorMa, Hen_HK
dc.contributor.authorXu, Sen_HK
dc.contributor.authorFan, STen_HK
dc.date.accessioned2010-09-06T08:54:38Z-
dc.date.available2010-09-06T08:54:38Z-
dc.date.issued2003en_HK
dc.identifier.citationCurrent Gene Therapy, 2003, v. 3 n. 4, p. 341-355en_HK
dc.identifier.issn1566-5232en_HK
dc.identifier.urihttp://hdl.handle.net/10722/84581-
dc.description.abstractThe hepatitis B virus (HBV) infection is a public health problem worldwide, particularly in East Asia. The current therapy of HBV infection is mostly based on chemical agents and cytokines that have been shown to provide limited efficacy and are also toxic to the human body. Gene therapy is a new therapeutic strategy against HBV infection, involving the transmission of gene drugs into liver cells by specific delivery systems and methods. Although this new anti-HBV infection technique is under active investigation, various promising anti-HBV viral gene drugs have been developed for gene therapy, including antisense RNA and DNA, hammerhead ribozymes, dominant negative HBV core mutants, single chain antibody, co-nuclease fusion protein, and antigen. In order to optimize their antiviral effects and/or enhance anti-HBV immunity, various novel gene delivery systems have also been developed to (specifically) deliver such DNA constructs into liver cells; some of them are viral vectors, such as adenoviral vectors, retroviral vectors and poxviral vectors, and even hepatitis B viral for its hepatocellular specificity. Others are non-viral vectors, in which naked DNA and liposomes are frequently used for DNA vaccine or nucleotide analogs for inhibiting HBV DNA polymerase. This review addresses various aspects of gene therapy for HBV infection, including gene drugs, delivery methods, animal model, and liver transplantation with combination therapy. It also discusses the problems that remain to be solved.en_HK
dc.languageengen_HK
dc.publisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cgt/index.htmen_HK
dc.relation.ispartofCurrent gene therapyen_HK
dc.titleMolecular therapeutics of HBV.en_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1566-5232&volume=3 &issue=4&spage=341&epage=355&date=2003&atitle=Molecular+therapeutics+of+HBVen_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid12871021-
dc.identifier.scopuseid_2-s2.0-0142223130en_HK
dc.identifier.hkuros84522en_HK
dc.identifier.volume3en_HK
dc.identifier.issue4en_HK
dc.identifier.spage341en_HK
dc.identifier.epage355en_HK
dc.publisher.placeNetherlandsen_HK
dc.identifier.scopusauthoridXu, R=7402813857en_HK
dc.identifier.scopusauthoridCai, K=7102517544en_HK
dc.identifier.scopusauthoridZheng, D=7202567084en_HK
dc.identifier.scopusauthoridMa, H=26643043900en_HK
dc.identifier.scopusauthoridXu, S=7404439649en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats